Effects of a frequent apolipoprotein E isoform, apoE4(Freiburg) (Leu28→Pro), on lipoproteins and the prevalence of coronary artery disease in Whites

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 5, 1999, Pages 1306-1315

  Orth, Matthias ^a,d   Weng, Wei ^c   Funke, Harald ^e   Steinmetz, Armin ^e   Assmann, Gerd ^e   Nauck, Matthias ^e   Dierkes, Jutta ^e   Ambrosch, Andreas ^e   Weisgraber, Karl H ^a,b   Mahley, Robert W ^a,b   Wieland, Heinrich ^e   Luley, Claus ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NONE

Author keywords

ApoE polymorphism; Atherosclerosis; Isoelectric focusing; Mutation

Indexed keywords

APOLIPOPROTEIN E; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; LEUCINE; LIPOPROTEIN; PROLINE; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; CAUCASIAN; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; ISOELECTRIC FOCUSING; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

EID: 0032912218     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.5.1306     Document Type: Article

References (59)

1. Havel RJ, Kotite L, Vigne JL, Kane JP, Tun P, Phillips N, Chen GC. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E: concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J Clin Invest. 1980;66:1351-1362.
2. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
3. Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 1994;269:13421-13428.
4. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by Cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101:689-695.
5. Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest. 1998;101:1726-1736.
6. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteinearginine interchange at a single site. J Biol Chem. 1982;257:2518-2521.
7. Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A. 1982;79: 4696-4700.
8. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265: 10771-10779.
9. Hixson JE. Apolipoprotein E polymorphisms affect atherosclerosis in young males: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb. 1991;11:1237-1244.
10. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160-165.
11. de Andrade M, Thandi I, Brown S, Gotto A, Jr, Patsch W, Boerwinkle E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet. 1995;56:1379-1390.
12. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
13. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349-1356.
14. Rall SC Jr, Weisgraber KH, Innerarity TL, Bersot TP, Mahley RW, Blum CB. Identification of a new structural variant of human apolipoprotein E, E2(Lys146→Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest. 1983;72:1288-1297.
15. Weisgraber KH, Rall SC Jr, Innerarity TL, Mahley RW, Kuusi T, Ehnholm C. A novel electrophoretic variant of human apolipoprotein E: identification and characterization of apolipoprotein E1. J Clin Invest. 1984;73:1024-1033.
16. Wardell MR, Brennan SO, Janus ED, Fraser R, Carrell RW. Apolipoprotein E2-Christchurch (136 Arg→Ser): new variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest. 1987;80:483-490.
17. Lalazar A, Weisgraber KH, Rall SC Jr, Giladi H, Innerarity TL, Levanon AZ, Boyles JK, Amit B, Gorecki M, Mahley RW, Vogel T. Site-specific mutagenesis of human apolipoprotein E: receptor binding activity of variants with single amino acid substitutions. J Biol Chem. 1988;263: 3542-3545.
18. Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim Biophys Acta. 1989;1005: 239-244.
19. Rall SC Jr, Newhouse YM, Clarke HR, Weisgraber KH, McCarthy BJ, Mahley RW, Bersot TP. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3: structure and genetics of an apolipoprotein E3 variant. J Clin Invest. 1989;83:1095-1101.
20. Mailly F, Xu CF, Xhignesse M, Lussier-Cacan S, Talmud PJ, Davignon J, Humphries SE, Nestruck AC. Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects. J Lipid Res. 1991; 32:613-620.
21. Feussner G, Funke H, Weng W, Assmann G, Lackner KJ, Ziegler R. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and ε1/'null' genotype. Eur J Clin Invest. 1992;22:599-608.
22. Wenham PR, McDowell IF, Hodges VM, McEneny J, MJ OK, Davies RJ, Nicholls DP, Trimble ER, Blundell G. Rare apolipoprotein E variant identified in a patient with type III hyperlipidaemia. Atherosclerosis. 1993;99:261-271.
23. Havekes L, de Wit E, Leuven JG, Klasen E, Utermann G, Weber W, Beisiegel U. Apolipoprotein E3-Leiden: a new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum Genet. 1986;73:157-163.
24. Wardell MR, Weisgraber KH, Havekes LM, Rall SC Jr. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem. 1989;264:21205-21210.
25. Dong LM, Yamamura T, Yamamoto A. Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts. Biochem Biophys Res Commun. 1990;168:409-414.
26. Wardell MR, Rall SC Jr, Schaefer EJ, Kane JP, Weisgraber KH. Two apolipoprotein E5 variants illustrate the importance of the position of additional positive charge on receptor-binding activity. J Lipid Res. 1991; 32:521-528.
27. Luley C, Haas B, Bührer B, Wieland H. Improvement of apolipoprotein E phenotyping by isoelectric focusing/immunofixation. Clin Chem. 1992; 38:168.
28. Orth M, Wahl S, Hanisch M, Friedrich I, Wieland H, Luley C. Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype. Biochim Biophys Acta. 1996;1303:22-30.
29. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Plainview, NY: Cold Spring Harbor Press; 1989.
30. Luley C. Entwicklung eines Verfahrens zur routinemäβigen Messung potentiell atherogener Lipoproteine in der Postprandialphase. Albert-Ludwigs Universität, Freiburg i. Br, 1992.
31. Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. HDLs and alimentary lipemia: studies in men with previous myocardial infarction at a young age. Arterioscler Thromb. 1993;13:11-22.
32. Cabezas MC, de Bruin TW, Jansen H, Kock LA, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb. 1993;13:804-814.
33. Luley C, Baumstark MW, Wieland H. Rapid apolipoprotein E phenotyping by immunofixation in agarose. J Lipid Res. 1991;32:880-883.
34. Gyllensten UB, Erlich HA. Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci U S A. 1988;85:7652-7656.
35. Rall SC Jr, Weisgraber KH, Mahley RW. Isolation and characterization of apolipoprotein E. Methods Enzymol. 1986;128:273-287.
36. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP. Apoprotein (E-A-II) complex of human plasma lipoproteins, II: receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E-A-II) complex. J Biol Chem. 1978;253:6289-6295.
37. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
38. Innerarity TL, Pitas RE, Mahley RW. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem. 1979;254:4186-4190.
39. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res. 1990;31:1503-1511.
40. Mackie A, Caslake MJ, Packard CJ, Shepherd J. Concentration and distribution of human plasma apolipoprotein E. Clin Chim Acta. 1981; 116:35-45.
41. Schwarz S, Haas B, Luley C, Schäfer JR, Steinmetz A. Quantification of apolipoprotein A-IV in human plasma by immunonephelometry. Clin Chem. 1994;40:1717-1721.
42. Orth M, Hanisch M, Kröning G, Porsch-Özcürümez M, Wieland H, Luley C. Fluorometric determination of retinyl esters in triglyceride-rich lipoproteins. Clin Chem. 1998;44:1459-1465.
43. Steinmetz A, Jakobs C, Motzny S, Kaffarnik H. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis. 1989;9:405-411.
44. Rall S Jr, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med. 1992;231:653-659.
45. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 1991;88: 2059-2066.
46. Weisgraber KH, Rall SC Jr, Mahley RW, Milne RW, Marcel YL, Sparrow JT. Human apolipoprotein E: determination of the heparin binding sites of apolipoprotein E3. J Biol Chem. 1986;261:2068-2076.
47. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science. 1991;252:1817-1822.
48. Pocovi M, Cenarro A, Civeira F, Myers RH, Casao E, Esteban M, Ordovas JM. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136→Ser) variant in multigenerational pedigree studies. Atherosclerosis. 1996;122:33-46.
49. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J. 1987;113:433-440.
50. Steinmetz A. Clinical implications of the apolipoprotein E polymorphism and genetic variants: current methods for apo E phenotyping. Ann Biol Clin (Paris). 1991;49:1-8.
51. Kervinen K, Savolainen MJ, Salokannel J, Hynninen A, Heikkinen J, Ehnholm C, Koistinen MJ, Kesäniemi YA. Apolipoprotein E, and B polymorphisms: longevity factors assessed in nonagenarians. Atherosclerosis. 1994;105:89-95.
52. Kataoka S, Robbins DC, Cowan LD, Go O, Yeh JL, Devereux RB, Fabsitz RR, Lee ET, Welty TK, Howard BV. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes: the Strong Heart Study. Arterioscler Thromb Vasc Biol. 1996; 16:918-925.
53. Braeckman L, De BD, Rosseneu M, De Backer G. Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins. Atherosclerosis. 1996;120: 67-73.
54. Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man, II: the role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet. 1987;27:567-582.
55. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
56. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
57. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease: implications for treatment. Arch Intern Med. 1992;152:28-34.
58. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA. Human apolipoprotein E: role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 1994;269:22358-22365.
59. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res. 1992;33:141-166.